Skip to main
SVRA
SVRA logo

Savara (SVRA) Stock Forecast & Price Target

Savara (SVRA) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Savara Inc. has recently exhibited strong financial growth potential, reflected in the increased DCF-derived price target, which was raised to $11 from $8, due to favorable updates and improved sales estimates. The projected peak annual U.S. sales for the molgramostim nebulizer solution, Molbreevi, have risen to $962 million, demonstrating a significant upward revision from previous estimates, as demand among pulmonologists appears robust. Additionally, the company anticipates a higher launch list price for Molbreevi, now estimated at $425,000, which bolsters expectations of worldwide peak sales reaching approximately $1.6 billion.

Bears say

Savara Inc. faces significant challenges that contribute to a negative outlook, primarily stemming from potential delays in regulatory approval and market entry for its pulmonary treatment, molgramostim, which could hinder sales and market share growth. Elevated research and development (R&D) and selling, general, and administrative (SG&A) expenses have also exceeded expectations, while total other income has fallen short, adding financial strain to the company's performance. Additionally, the pushback of the expected commercial launch in Japan to 2028 and a reduced probability of success from 90% to 75% further underscore concerns regarding Savara's ability to effectively penetrate key markets.

Savara (SVRA) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Savara and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Savara (SVRA) Forecast

Analysts have given Savara (SVRA) a Buy based on their latest research and market trends.

According to 6 analysts, Savara (SVRA) has a Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Savara (SVRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.